|4.38||-0.0800||-1.79%||Vol 1.77M||1Y Perf -56.49%|
|Oct 3rd, 2023 16:00 DELAYED|
|- -||-0.05 -1.11%|
|Target Price||25.29||Analyst Rating||Strong Buy 1.00|
|Potential %||477.40||Finscreener Ranking||★★★★★ 72.26|
|Insiders Trans % 3/6/12 mo.||100/100/60||Value Ranking||★★★★★ 64.52|
|Insiders Value % 3/6/12 mo.||100/100/0||Growth Ranking||★★★★★ 89.12|
|Insiders Shares Cnt. % 3/6/12 mo.||100/100/35||Income Ranking||— -|
|Price Range Ratio 52W %||-0.47||Earnings Rating||—|
|Market Cap||1.27B||Earnings Date||14th Nov 2023|
Today's Price Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Q04 2022||0.01||-0.10||-1 100.00|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||14th Nov 2023|
|Estimated EPS Next Report||-0.14|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.75M|
|Avg. Monthly Volume||1.71M|
|Avg. Quarterly Volume||1.92M|
AbCellera Biologics Inc. (NASDAQ: ABCL) stock closed at 4.46 per share at the end of the most recent trading day (a -3.04% change compared to the prior day closing price) with a volume of 2.38M shares and market capitalization of 1.27B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 174 people. AbCellera Biologics Inc. CEO is Carl L.G. Hansen.
The one-year performance of AbCellera Biologics Inc. stock is -56.49%, while year-to-date (YTD) performance is -55.97%. ABCL stock has a five-year performance of %. Its 52-week range is between 4.43 and 14.97, which gives ABCL stock a 52-week price range ratio of -0.47%
AbCellera Biologics Inc. currently has a PE ratio of 12.00, a price-to-book (PB) ratio of 2.18, a price-to-sale (PS) ratio of 5.89, a price to cashflow ratio of 12.90, a PEG ratio of -, a ROA of 19.51%, a ROC of 21.51% and a ROE of 24.14%. The company’s profit margin is 40.62%, its EBITDA margin is 62.20%, and its revenue ttm is $463.88 Million , which makes it $1.62 revenue per share.
Of the last four earnings reports from AbCellera Biologics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.14 for the next earnings report. AbCellera Biologics Inc.’s next earnings report date is 14th Nov 2023.
The consensus rating of Wall Street analysts for AbCellera Biologics Inc. is Strong Buy (1), with a target price of $25.29, which is +477.40% compared to the current price. The earnings rating for AbCellera Biologics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
AbCellera Biologics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
AbCellera Biologics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 22.03, ATR14 : 0.22, CCI20 : -148.03, Chaikin Money Flow : -0.38, MACD : -0.32, Money Flow Index : 44.09, ROC : -13.73, RSI : 24.78, STOCH (14,3) : 2.91, STOCH RSI : 0.00, UO : 28.56, Williams %R : -97.09), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of AbCellera Biologics Inc. in the last 12-months were: Andrew Booth (Option Excercise at a value of $9 500), Carl L.G. Hansen (Option Excercise at a value of $303 075)
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.